Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=94"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=94

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01467466-f1c480e5",
        "title": "Sodium Bicarbonate vs Saline: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride.",
        "summary": "111 of 2393 against 116 of 2379; risk difference -0.2 points, 95% interval -1.5 to 1.0; NCT01467466, Prevention of Serious Adverse Events Following Angiography",
        "record": "/library/comparisons/NCT01467466-f1c480e5",
        "nct_id": "NCT01467466",
        "kind": "outcome",
        "participants": 4772,
        "risk_difference": {
          "value": -0.002374692755790636,
          "lower": -0.01454520879722701,
          "upper": 0.009768088710277532
        },
        "group_1": "111 of 2,393",
        "group_2": "116 of 2,379",
        "difference": "-0.2 points",
        "interval": "-1.5 to 1.0",
        "trial_title": "Prevention of Serious Adverse Events Following Angiography"
      },
      {
        "id": "NCT01358877-sae",
        "title": "Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events",
        "summary": "792 of 2364 against 686 of 2405; risk difference 5.0 points, 95% interval 2.4 to 7.6; NCT01358877, A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer",
        "record": "/library/comparisons/NCT01358877-sae",
        "nct_id": "NCT01358877",
        "kind": "serious-adverse-events",
        "participants": 4769,
        "risk_difference": {
          "value": 0.04978629547157465,
          "lower": 0.023535280250455357,
          "upper": 0.07595430297801115
        },
        "group_1": "792 of 2,364",
        "group_2": "686 of 2,405",
        "difference": "5.0 points",
        "interval": "2.4 to 7.6",
        "trial_title": "A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=95",
  "request_id": "8SKxvKEjyoSc6fpI"
}